GA101
Showing 1 - 25 of 851
Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, ABT-199)
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
-
Cologne, GermanyGerman CLL Study Group
Sep 14, 2022
Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, CAL-101)
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
-
Cologne, GermanyGerman CLL Study Group
Apr 29, 2022
Lymphoma, Non-Hodgkin Trial in Mainz (Obinutuzumab and Pixantrone)
Completed
- Lymphoma, Non-Hodgkin
- Obinutuzumab and Pixantrone
-
Mainz, RLP, GermanyDepartment of Hematology, Oncology and Pneumology; University Me
Mar 30, 2022
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)
Active, not recruiting
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
-
Borddeaux Cedex, France
- +9 more
Nov 11, 2022
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib and obinutuzumab
-
Milano, MI, ItalyStrategic Research Program on CLL
Apr 2, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 2, 2022
Follicular Lymphoma, Tumor Trial in Houston (Obinutuzumab, CC-99282)
Not yet recruiting
- Follicular Lymphoma
- Tumor
-
Houston, TexasM D Anderson Cancer Center
Oct 30, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Cyclophosphamide, Fludarabine Phosphate, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Cyclophosphamide
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Chronic Lymphocytic Leukemia Trial in Portland (drug, procedure, biological, other)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- +8 more
-
Portland, OregonOHSU Knight Cancer Institute
Jul 12, 2023
Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)
Recruiting
- Marginal Zone Lymphoma
- Obinutuzumab, lenalidomide
-
Tianjin, Tian, ChinaInstitute of Hematology & Blood Diseases Hospital
Apr 27, 2023
Chronic Lymphoid Leukemia Trial in Germany (Bendamustine, Obinutuzumab, Acalabrutinib)
Active, not recruiting
- Chronic Lymphoid Leukemia
- Bendamustine
- +3 more
-
Dresden, Germany
- +16 more
Nov 8, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Orelabrutinib
- +3 more
-
Nanjin, Jiangsu, ChinaDepartment of Haematology, the First Affiliated Hospital of Nanj
Apr 12, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)
Completed
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Ibrutinib
- Obinutuzumab
-
Portland, OregonOHSU Knight Cancer Institute
Dec 10, 2021
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in
Recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +5 more
- Ibrutinib
- +2 more
-
Fresno, California
- +2 more
Jan 24, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +4 more
-
Scottsdale, Arizona
- +2 more
Jan 5, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022
Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)
Not yet recruiting
- Mantle Cell Lymphoma
- Acalabrutinib
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 20, 2023
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)
Not yet recruiting
- Follicular Lymphoma
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Indolent Non-hodgkin Lymphoma Trial in München (Obinutuzumab, Bendamustine)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
München, Bavaria, GermanyKlinikum der Universität München
Jul 23, 2021
Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Richter's Transformation
- Glofitamab
- +4 more
-
Boston, Massachusetts
- +1 more
Sep 12, 2023
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte
Not yet recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +2 more
- Biopsy
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
May 15, 2023